Search results
Results from the WOW.Com Content Network
Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). Sensitive molecular tests are either in development or available to test for MRD.
Animation of a cycloidal drive. A cycloidal drive or cycloidal speed reducer is a mechanism for reducing the speed of an input shaft by a certain ratio. Cycloidal speed reducers are capable of relatively high ratios in compact sizes with very low backlash. [1] The input shaft drives an eccentric bearing that in turn drives the cycloidal disc in ...
Nabtesco (ナブテスコ株式会社, Nabutesuko Kabushiki-gaisha) is a Japanese engineering company that specializes in gearboxes, rotors, motors and robotics. History [ edit ]
Besides understanding the underlying genetic mechanisms that initiate or drive cancer progression, oncogenomics targets personalized cancer treatment. Cancer develops due to DNA mutations and epigenetic alterations that accumulate randomly. Identifying and targeting the mutations in an individual patient may lead to increased treatment efficacy.
The Network of Cancer Genes (NCG) is a freely accessible web resource of genes that, when altered in their sequence, drive clonal expansion of normal tissues (healthy drivers) or cancer (cancer drivers). The project was launched in 2010 and has reached its 7th release in 2022.
The chemotherapy drug 5-FU can be toxic to some people with cancer. A quick, cheap test can show if chemo is safe for a patient, but few doctors order it. ... treatment for metastatic breast ...
Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells.
In July this year, the FDA approved Guardant Health Inc.’s (NASDAQ:GH) Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.